Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07340047 · ClinicalTrials.gov registry record · Phase 1
H1ssF Flu Vaccine Clinical Trial
A Phase 1 study, sponsored by University of Minnesota.
- Not yet
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT07340047: Clinical Trial Phase 1 study, sponsored by University of Minnesota.
NCT07340047 is a Phase 1 study that has not yet begun recruiting, run by University of Minnesota. The registered enrollment target is 112 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07340047, a Phase 1 study, has not yet begun recruiting, sponsored by University of Minnesota.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
This is a two-arm, open-label, randomized, phase 1, controlled clinical trial intended to evaluate the safety and immunologic response to the experimental vaccine H1ssF (H1 stabilized stem ferritin nanoparticle) and the seasonal flu vaccine Flucelvax.
Interventions
- BIOLOGICAL H1ssF vaccine
- BIOLOGICAL Flucelvax seasonal vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 1 |
What is known before NCT07340047 opens enrollment
NCT07340047 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which H1ssF vaccine is the first listed.
NCT07340047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07340047 about?
NCT07340047 is a clinical study titled "H1ssF Flu Vaccine Clinical Trial". This is a two-arm, open-label, randomized, phase 1, controlled clinical trial intended to evaluate the safety and immunologic response to the experimental vaccine H1ssF (H1 stabilized stem ferritin nanoparticle) and the seasonal flu vaccine Flucelvax.
What is the current status of trial NCT07340047?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2026-08-01. Estimated completion is 2028-03-01.
What interventions are being tested in trial NCT07340047?
The interventions under investigation include: H1ssF vaccine (BIOLOGICAL), Flucelvax seasonal vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07340047?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07340047's enrollment target sits among peer trials
112 508th of 2000 higher than 1,489 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI